

Small Cell Lung Carcinoma Small Cell Lung Cancer

**A Study of Carboplatin Plus Etoposide With or Without
Atezolizumab in Participants With Untreated Extensive-Stage (ES)
Small Cell Lung Cancer (SCLC)**

Trial Status
Completed

Trial Runs In
21 Countries

Trial Identifier
NCT02763579 2015-004861-97
GO30081

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naïve participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02763579 2015-004861-97 GO30081
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No